Accredited Investors’s Humacyte HUMA Stock Holding History

Accredited Investors’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.2K	Buy	+15,600	New	+$14.5K	﹤0.01%	299

Other funds holding HUMA

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

LJI Wealth Management Indianapolis, Indiana $714M AUM 21.49% 1-Year Est. Return

United Asset Strategies Garden City, New York $1.41B AUM 27.73% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Clarus Wealth Advisors Peoria, Arizona $260M AUM 27.97% 1-Year Est. Return

Accredited Investors's HUMA Position: Q2 2026 in Review

Accredited Investors opened a new position in Humacyte (HUMA) in Q2 2026: 15,600 shares worth $12.2K. The stake represents ﹤0.01% of the portfolio and ranks #299 among its holdings.

43 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

Accredited Investors held 15,600 shares of Humacyte worth $12.2K as of Q2 2026.
Humacyte was a new Accredited Investors position in Q2 2026.
Humacyte made up ﹤0.01% of Accredited Investors's portfolio in Q2 2026, its #299 holding.
43 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Accredited Investors's 13F filing for Q2 2026, filed 21 Jul 2026.